New combo aims to stop dangerous rebleeds in liver patients
NCT ID NCT07465471
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tests whether adding midodrine to the standard drug carvedilol can prevent early rebleeding in people with liver cirrhosis who have had a variceal bleed. About 210 adults with moderate to severe cirrhosis will be randomly assigned to receive either both drugs or carvedilol alone. The goal is to see if the combination reduces the chance of rebleeding within 6 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, 110070, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.